Skip to main content
David Bond, MD, Hematology, Columbus, OH

David Alan Bond MD

Hematologic Oncology


Physician

Join to View Full Profile
  • 460 W 10th AveFl 5Columbus, OH 43210

  • Phone+1 614-293-3989

  • Fax+1 614-293-4812

Dr. Bond is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Ohio State University Hospital
    Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2016 - 2019
  • Ohio State University Hospital
    Ohio State University HospitalResidency, Internal Medicine, 2012 - 2015
  • Indiana University School of Medicine
    Indiana University School of MedicineClass of 2012

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2012 - 2027
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Hematology
    American Board of Internal Medicine Hematology
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Abstracts/Posters

  • Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma
    David A. Bond, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma
    David A. Bond, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-Worl...
    David A. Bond, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • A Phase I Study of Nivolumab and Lenalidomide in Relapsed/ Refractory B Cell Lymphoma 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Second cancer incidence in CLL patients receiving BTK inhibitors. 
    2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

  • Mosunetuzumab in Follicular Lymphoma: Durable Responses and Manageable Safety
    Mosunetuzumab in Follicular Lymphoma: Durable Responses and Manageable SafetyDecember 19th, 2024
  • Surviving CLL: Higher Risk of Other Cancer DXs
    Surviving CLL: Higher Risk of Other Cancer DXsFebruary 17th, 2023

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: